# Lantronix Inc: financial statements, quarterly

LTRX · Nasdaq · CIK 1114925 · [Technology](/sectors/technology.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/ltrx.md) · [Financials](/companies/ltrx/financials.md) · [Filings](/companies/ltrx/filings.md) · [Insiders](/companies/ltrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ltrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [33.0](/filings/0001683168-24-007780.md) | [37.0](/filings/0001683168-25-000793.md) | [41.2](/filings/0001683168-25-003319.md) | [49.1 d](/filings/0001683168-25-006532.md) | [34.4](/filings/0001683168-25-008030.md) | [31.2](/filings/0001683168-26-000774.md) | [28.5](/filings/0001683168-26-003564.md) | [28.8 d](/filings/0001683168-26-006754.md) | [29.8](/filings/0001683168-25-008030.md) | [29.8](/filings/0001683168-26-000774.md) | [30.2](/filings/0001683168-26-003564.md) | [31.2 d](/filings/0001683168-26-006754.md) |
| Cost of revenue | $m | [18.9](/filings/0001683168-24-007780.md) | [22.0](/filings/0001683168-25-000793.md) | [24.7](/filings/0001683168-25-003319.md) | [(65.2) d](/filings/0001683168-25-006532.md) | [19.9](/filings/0001683168-25-008030.md) | [17.9](/filings/0001683168-26-000774.md) | [16.1](/filings/0001683168-26-003564.md) | [(0.1) d](/filings/0001683168-26-006754.md) | [0.1](/filings/0001683168-25-008030.md) | [16.8](/filings/0001683168-26-000774.md) | [17.2](/filings/0001683168-26-003564.md) | [0.0 d](/filings/0001683168-26-006754.md) |
| Gross profit | $m | [14.1](/filings/0001683168-24-007780.md) | [15.0](/filings/0001683168-25-000793.md) | [16.5](/filings/0001683168-25-003319.md) | [18.7 d](/filings/0001683168-25-006532.md) | [14.5](/filings/0001683168-25-008030.md) | [13.3](/filings/0001683168-26-000774.md) | [12.4](/filings/0001683168-26-003564.md) | [11.5 d](/filings/0001683168-26-006754.md) | [13.3](/filings/0001683168-25-008030.md) | [13.0](/filings/0001683168-26-000774.md) | [13.0](/filings/0001683168-26-003564.md) | [13.6 d](/filings/0001683168-26-006754.md) |
| Research and development | $m | [5.1](/filings/0001683168-24-007780.md) | [4.7](/filings/0001683168-25-000793.md) | [5.2](/filings/0001683168-25-003319.md) | [5.3 d](/filings/0001683168-25-006532.md) | [5.0](/filings/0001683168-25-008030.md) | [5.0](/filings/0001683168-26-000774.md) | [4.5](/filings/0001683168-26-003564.md) | [4.2 d](/filings/0001683168-26-006754.md) | [4.6](/filings/0001683168-25-008030.md) | [4.6](/filings/0001683168-26-000774.md) | [4.1](/filings/0001683168-26-003564.md) | [4.2 d](/filings/0001683168-26-006754.md) |
| Selling, general and administrative | $m | [9.2](/filings/0001683168-24-007780.md) | [10.2](/filings/0001683168-25-000793.md) | [9.8](/filings/0001683168-25-003319.md) | [11.1 d](/filings/0001683168-25-006532.md) | [9.5](/filings/0001683168-25-008030.md) | [8.8](/filings/0001683168-26-000774.md) | [9.0](/filings/0001683168-26-003564.md) | [9.0 d](/filings/0001683168-26-006754.md) | [9.5](/filings/0001683168-25-008030.md) | [8.7](/filings/0001683168-26-000774.md) | [9.4](/filings/0001683168-26-003564.md) | [9.3 d](/filings/0001683168-26-006754.md) |
| Operating income | $m | [(1.6)](/filings/0001683168-24-007780.md) | [(1.8)](/filings/0001683168-25-000793.md) | [(0.1)](/filings/0001683168-25-003319.md) | [0.6 d](/filings/0001683168-25-006532.md) | [(2.1)](/filings/0001683168-25-008030.md) | [(2.2)](/filings/0001683168-26-000774.md) | [(3.6)](/filings/0001683168-26-003564.md) | [(3.1) d](/filings/0001683168-26-006754.md) | [(1.5)](/filings/0001683168-25-008030.md) | [(1.1)](/filings/0001683168-26-000774.md) | [(1.1)](/filings/0001683168-26-003564.md) | [(0.4) d](/filings/0001683168-26-006754.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.0)](/filings/0001683168-24-007780.md) | [0.6](/filings/0001683168-25-000793.md) | [0.2](/filings/0001683168-25-003319.md) | [0.0 d](/filings/0001683168-25-006532.md) | [0.2](/filings/0001683168-25-008030.md) | [0.1](/filings/0001683168-26-000774.md) | [0.1](/filings/0001683168-26-003564.md) | [(0.7) d](/filings/0001683168-26-006754.md) | [0.0](/filings/0001683168-25-008030.md) | [0.2](/filings/0001683168-26-000774.md) | [0.0](/filings/0001683168-26-003564.md) | [(0.0) d](/filings/0001683168-26-006754.md) |
| Net income | $m | [(1.9)](/filings/0001683168-24-007780.md) | [(2.6)](/filings/0001683168-25-000793.md) | [(0.4)](/filings/0001683168-25-003319.md) | [0.4 d](/filings/0001683168-25-006532.md) | [(2.5)](/filings/0001683168-25-008030.md) | [(2.4)](/filings/0001683168-26-000774.md) | [(3.9)](/filings/0001683168-26-003564.md) | [(2.6) d](/filings/0001683168-26-006754.md) | [(1.4)](/filings/0001683168-25-008030.md) | [(1.3)](/filings/0001683168-26-000774.md) | [(1.2)](/filings/0001683168-26-003564.md) | [(0.3) d](/filings/0001683168-26-006754.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001683168-24-007780.md) | [(0.07)](/filings/0001683168-25-000793.md) | [(0.01)](/filings/0001683168-25-003319.md) | not reported | [(0.07)](/filings/0001683168-25-008030.md) | [(0.06)](/filings/0001683168-26-000774.md) | [(0.10)](/filings/0001683168-26-003564.md) | not reported | [(0.04)](/filings/0001683168-25-008030.md) | [(0.03)](/filings/0001683168-26-000774.md) | [(0.03)](/filings/0001683168-26-003564.md) | not reported |
| Basic EPS | $ per share | [(0.05)](/filings/0001683168-24-007780.md) | [(0.07)](/filings/0001683168-25-000793.md) | [(0.01)](/filings/0001683168-25-003319.md) | not reported | [(0.07)](/filings/0001683168-25-008030.md) | [(0.06)](/filings/0001683168-26-000774.md) | [(0.10)](/filings/0001683168-26-003564.md) | not reported | [(0.04)](/filings/0001683168-25-008030.md) | [(0.03)](/filings/0001683168-26-000774.md) | [(0.03)](/filings/0001683168-26-003564.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold, us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [19.5](/filings/0001683168-23-007735.md) | [22.1](/filings/0001683168-24-000785.md) | [24.6](/filings/0001683168-24-002895.md) | [26.2](/filings/0001683168-25-006532.md) | [26.4](/filings/0001683168-24-007780.md) | [19.2](/filings/0001683168-25-000793.md) | [20.0](/filings/0001683168-25-003319.md) | [20.1](/filings/0001683168-26-006754.md) | [22.2](/filings/0001683168-25-008030.md) | [23.0](/filings/0001683168-26-000774.md) | [23.5](/filings/0001683168-26-003564.md) | [60.5](/filings/0001683168-26-006754.md) |
| Current assets | $m | [98.9](/filings/0001683168-23-007735.md) | [99.9](/filings/0001683168-24-000785.md) | [97.9](/filings/0001683168-24-002895.md) | [89.0](/filings/0001683168-25-006532.md) | [92.6](/filings/0001683168-24-007780.md) | [85.6](/filings/0001683168-25-000793.md) | [76.5](/filings/0001683168-25-003319.md) | [77.4](/filings/0001683168-26-006754.md) | [74.4](/filings/0001683168-25-008030.md) | [77.9](/filings/0001683168-26-000774.md) | [77.0](/filings/0001683168-26-003564.md) | [117](/filings/0001683168-26-006754.md) |
| Total assets | $m | [152](/filings/0001683168-23-007735.md) | [152](/filings/0001683168-24-000785.md) | [147](/filings/0001683168-24-002895.md) | [136](/filings/0001683168-25-006532.md) | [138](/filings/0001683168-24-007780.md) | [134](/filings/0001683168-25-000793.md) | [124](/filings/0001683168-25-003319.md) | [124](/filings/0001683168-26-006754.md) | [120](/filings/0001683168-25-008030.md) | [122](/filings/0001683168-26-000774.md) | [120](/filings/0001683168-26-003564.md) | [160](/filings/0001683168-26-006754.md) |
| Current liabilities | $m | [48.8](/filings/0001683168-23-007735.md) | [48.0](/filings/0001683168-24-000785.md) | [43.6](/filings/0001683168-24-002895.md) | [30.2](/filings/0001683168-25-006532.md) | [35.5](/filings/0001683168-24-007780.md) | [33.4](/filings/0001683168-25-000793.md) | [28.6](/filings/0001683168-25-003319.md) | [30.4](/filings/0001683168-26-006754.md) | [24.7](/filings/0001683168-25-008030.md) | [28.4](/filings/0001683168-26-000774.md) | [28.1](/filings/0001683168-26-003564.md) | [32.1](/filings/0001683168-26-006754.md) |
| Total liabilities | $m | [75.4](/filings/0001683168-23-007735.md) | [74.8](/filings/0001683168-24-000785.md) | [69.3](/filings/0001683168-24-002895.md) | [54.9](/filings/0001683168-25-006532.md) | [58.9](/filings/0001683168-24-007780.md) | [56.3](/filings/0001683168-25-000793.md) | [48.7](/filings/0001683168-25-003319.md) | [49.3](/filings/0001683168-26-006754.md) | [45.1](/filings/0001683168-25-008030.md) | [47.3](/filings/0001683168-26-000774.md) | [45.5](/filings/0001683168-26-003564.md) | [41.1](/filings/0001683168-26-006754.md) |
| Long-term debt | $m | [15.5](/filings/0001683168-23-007735.md) | [14.7](/filings/0001683168-24-000785.md) | [14.0](/filings/0001683168-24-002895.md) | [13.2](/filings/0001683168-25-006532.md) | [12.4](/filings/0001683168-24-007780.md) | [11.6](/filings/0001683168-25-000793.md) | [9.5](/filings/0001683168-25-003319.md) | [8.7](/filings/0001683168-26-006754.md) | [10.7](/filings/0001683168-25-008030.md) | [9.7](/filings/0001683168-26-000774.md) | [8.7](/filings/0001683168-26-003564.md) | [0.0](/filings/0001683168-26-006754.md) |
| Current portion of debt | $m | [3.0](/filings/0001683168-23-007735.md) | [3.0](/filings/0001683168-24-000785.md) | [3.0](/filings/0001683168-24-002895.md) | [3.0](/filings/0001683168-25-006532.md) | [3.1](/filings/0001683168-24-007780.md) | [3.1](/filings/0001683168-25-000793.md) | [3.1](/filings/0001683168-25-003319.md) | [3.1](/filings/0001683168-26-006754.md) | [0.0](/filings/0001683168-25-008030.md) | [0.0](/filings/0001683168-26-000774.md) | [0.0](/filings/0001683168-26-003564.md) | [0.0](/filings/0001683168-26-006754.md) |
| Short-term borrowings | $m | [3.0](/filings/0001683168-23-007735.md) | [3.0](/filings/0001683168-24-000785.md) | [3.0](/filings/0001683168-24-002895.md) | [3.0](/filings/0001683168-25-006532.md) | [3.1](/filings/0001683168-24-007780.md) | [3.1](/filings/0001683168-25-000793.md) | [3.1](/filings/0001683168-25-003319.md) | [3.1](/filings/0001683168-26-006754.md) | [0.0](/filings/0001683168-25-008030.md) | [0.0](/filings/0001683168-26-000774.md) | [0.0](/filings/0001683168-26-003564.md) | [0.0](/filings/0001683168-26-006754.md) |
| Shareholders' equity | $m | [77.0](/filings/0001683168-25-000793.md) | [76.8](/filings/0001683168-25-003319.md) | [78.1](/filings/0001683168-25-003319.md) | [81.4](/filings/0001683168-26-006754.md) | [78.9](/filings/0001683168-26-000774.md) | [77.9](/filings/0001683168-26-003564.md) | [75.5](/filings/0001683168-26-003564.md) | [74.4](/filings/0001683168-26-006754.md) | [74.5](/filings/0001683168-26-000774.md) | [74.4](/filings/0001683168-26-003564.md) | [74.5](/filings/0001683168-26-003564.md) | [119](/filings/0001683168-26-006754.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [7,498](/filings/0001683168-24-007780.md) | [5,254 d](/filings/0001683168-25-000793.md) | [3,596 d](/filings/0001683168-25-003319.md) | [2,275 d](/filings/0001683168-25-006532.md) | [2,663](/filings/0001683168-25-008030.md) | [340 d](/filings/0001683168-26-000774.md) | [3,230 d](/filings/0001683168-26-003564.md) | [1,052 d](/filings/0001683168-26-006754.md) | [3,605](/filings/0001683168-25-008030.md) | [2,178 d](/filings/0001683168-26-000774.md) | [2,167 d](/filings/0001683168-26-003564.md) | [1,927 d](/filings/0001683168-26-006754.md) |
| Capital expenditure | $k | [486](/filings/0001683168-24-007780.md) | [703 d](/filings/0001683168-25-000793.md) | [136 d](/filings/0001683168-25-003319.md) | [154 d](/filings/0001683168-25-006532.md) | [157](/filings/0001683168-25-008030.md) | [84.0 d](/filings/0001683168-26-000774.md) | [121 d](/filings/0001683168-26-003564.md) | [143 d](/filings/0001683168-26-006754.md) | [74.0](/filings/0001683168-25-008030.md) | [92.0 d](/filings/0001683168-26-000774.md) | [237 d](/filings/0001683168-26-003564.md) | [209 d](/filings/0001683168-26-006754.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [35.4](/filings/0001683168-23-007735.md) | [36.4](/filings/0001683168-24-000785.md) | [36.5](/filings/0001683168-24-002895.md) | [37.0](/filings/0001683168-24-007780.md) | [37.4](/filings/0001683168-25-000793.md) | [37.5](/filings/0001683168-25-003319.md) | [38.0](/filings/0001683168-25-008030.md) | [38.6](/filings/0001683168-26-000774.md) | [38.8](/filings/0001683168-26-003564.md) | [39.2](/filings/0001683168-25-008030.md) | [39.5](/filings/0001683168-26-000774.md) | [39.7](/filings/0001683168-26-003564.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 46,705,312 at 2026-08-20, from the cover of the [10-K filed 2026-08-27](/filings/0001683168-26-006754.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.